期刊文献+

晚期肿瘤胰岛素增强化疗毒副反应的观察及护理 被引量:7

Side effects observation and nursing of insulin-enhance chemotherapy foradvanced cancer patients
下载PDF
导出
摘要 目的观察胰岛素增强疗法治疗晚期肿瘤的近期疗效和毒副反应,以及患者的耐受性。探求治疗晚期肿瘤的新方法以及相应的护理对策。方法对16例符合入选标准的晚期肿瘤患者进行胰岛素增强化疗,并在化疗前、化疗中、化疗后进行有效的心理护理、预处理、密切病情观察、微量血糖的监测、低血糖反应的预防及终止后的护理。结果本组病人在进行胰岛素增强疗法监测过程中,通过实施一系列护理措施,减少了并发症的发生,均能顺利完成化疗周期。结论在胰岛素增强化疗中,采取积极有效的护理措施,可减轻病人痛苦,及时发现并处理并发症,保证患者对化疗方案的依从性,从而达到控制症状、延长生存期、提高患者生活质量的目的。
出处 《护士进修杂志》 2013年第5期437-439,共3页 Journal of Nurses Training
关键词 胰岛素增强化疗 晚期肿瘤 毒副反应 临床护理 lrisulin-enhance chemotherapy Advanced cancer Toxicity side effects Clinical nursing
  • 相关文献

参考文献7

  • 1Bartucci M. Estrogen receptor (ER) positive MCF 7 and ER negative MDA-MB-231 breast cancer cells[J].Cancer Res, 2001, 61(18): 6747-6754.
  • 2All-Ericsson C, Oirnita L, Seregard S, et al. Insulin like grow factorl reeptor in uveal melanoma a predictor for metastatic disease and a potential therapeutic target [J].Invest ophthal mol Vis Sci, 2002, 43(1) : 1-8.
  • 3Matthias MWeber, Christian. Fotmer, Sun Bin IJin, et al. O- ver-expression of the insulin-like growth factor 1 receptor in human colon carcinomas [J]. Cancer, 2002, 95: 2086-2095.
  • 4Giles O, Hellawell, Gareth DH, et al. Exoression of the type 1 insulin-like growth factor receptor is up-regulared in primary prostate cancer and commonly persists in metastatic disease [J]. CancerRes, 2002, 62: 2942-2966.
  • 5郭桂芳,姚兰.外科护理学[M].北京:人民卫生出版社,2005:25-31.
  • 6张涛,陶雪斌,邓宏明.血糖仪测定血糖值可靠性研究[J].护士进修杂志,2002,17(12):890-891. 被引量:53
  • 7冯奉仪,何晓慧,石远凯,李丽庆,王华庆,佟仲生,张其忠,陈强,黄苹,张茂宏,孔北华,黎莉,张阳,佟知拥,朱允中,史鹤龄.拓扑替康治疗小细胞肺癌和复发性卵巢癌的临床研究[J].中华肿瘤杂志,2001,23(2):155-158. 被引量:20

二级参考文献12

  • 1Grant SC,Gralla RJ,Kriss MG,et al.Single agent chemotherapy trial in small cell lung cancer, 1970 to 1990: the case for studies in previously treated patients[].Journal of Clinical Oncology.1992
  • 2Albain KS,Crowley JJ,Hutchins L,et al.Predictors of survival following relapse or progression of small cell lung cancer[].Cancer.1993
  • 3Armstrong D,Rowinsky E,Freedman R,et al.A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer[].Proceedings of the American Society of Clinical Oncology.1995
  • 4Perel Soler R,Glisson BE,Lee JS,et al.Treatment of patients with small cell lung cancer refractory to etoposide and cisplatin with the topoismerase I poison[].Journal of Clinical Oncology.1996
  • 5Shiller JH,Kim K,Hutson P,et al.Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: an eastern cooperative oncology group trial[].Journal of Clinical Oncology.1996
  • 6Von Pawel J,Schiller JH,Shepherd FA,et al.Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[].Journal of Clinical Oncology.1999
  • 7Von Pawel J,Depierre A,Hans K,et al.Topotecan (Hycamtin) in small cell lung cancer after failure of first line therapy-multicentre phase II study[].European Journal of Cancer.1997
  • 8Eckardt J,Gralla R,Palmer MC,et al.Topotecan as second line therapy in patients with small cell lung cancer: a phase II study[].Oncology.1996
  • 9Huinink WB,Martin G,Games C,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer[].Journal of Clinical Oncology.1997
  • 10Kollmannsberger C,Mross K,Jakob A,et al.Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience[].Oncology.1999

共引文献72

同被引文献26

引证文献7

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部